Insulet (MEX:PODD) Other Financing: MXN2,838 Mil (TTM As of Mar. 2026)


MEX:PODD Insulet Corp MEX:PODD
75 GF Score
Price MXN2,780.00
GF Value MXN6,698.99
Valuation Significantly Undervalued
View Full Analysis

What is Insulet Other Financing?

Insulet MEX:PODD 75 Other Financing is MXN2,838 Mil as of Mar. 2026. GuruFocus rates MEX:PODD with a GF Score™ of 75/100 and a GF Value™ of MXN6,698.99 (Significantly Undervalued).

Insulet's Other Financing for the three months ended in Mar. 2026 was MXN-278 Mil.

Insulet's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was MXN2,838 Mil.

Insulet Other Financing Historical Data

* Premium members only.

The historical data trend for Insulet's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet Other Financing Chart

Insulet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -178.47 -9.75 227.46 262.78 3,104.18

Insulet Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.92 1,284.15 1,672.99 158.45 -277.70
MEX:PODD
75GF Score
Insulet Corp MEX:PODD
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insulet Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN2,838 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of MXN2,838 Mil mean?
Insulet (MEX:PODD) has a Other Financing of MXN2,838 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Insulet and its competitors.
Is Insulet's Other Financing too high?
Insulet's current Other Financing is MXN2,838 Mil. Overall, Insulet has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Other Financing compare to GMED and PEN?
Insulet's Other Financing of MXN2,838 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Insulet and its competitors. Insulet's current Other Financing is MXN2,838 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (MEX:PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN6,698.99, compared to a current price of MXN2,780.00 — trading 58.5% below its estimated fair value. The current Other Financing is MXN2,838 Mil. Insulet's overall GF Score™ is 75/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Insulet (MEX:PODD), the current Other Financing is MXN2,838 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (MEX:PODD) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of MXN2,780.00 is trading 58.5% below its estimated GF Value™ of MXN6,698.99. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for MEX:PODD:

  • Other Financing: MXN2,838 Mil
  • GF Value™: MXN6,698.99 vs. price of MXN2,780.00 (58.5% below fair value)
  • GF Score™: 75/100

No single metric tells the full story. See the MEX:PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
75GF Score

Get the complete analysis for MEX:PODD

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,780.00
Price
MXN6,698.99
GF Value